Physician profile
Brian Wright Roe
NPI 1396007894
$4,531.47
in general payments reported to CMS, 2019-2025
23 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $374 · 2021: $305 · 2022: $1,455 · 2023: $499 · 2024: $566 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,139.84 | 2021-2025 | Resolute Onyx |
| Medtronic Vascular, INC. | $703.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $469.36 | 2021-2025 | |
| Amgen INC. | $361.52 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $326.84 | 2019-2025 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $294.91 | 2022-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $217.40 | 2019-2025 | Lifevest |
| Pfizer INC. | $169.87 | 2019-2025 | |
| Avinger INC. | $109.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $106.35 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $97.73 | 2019-2024 | Xarelto |
| Biotronik INC. | $95.62 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $70.33 | 2019-2024 | |
| Abiomed | $60.18 | 2022-2023 | Impella |
| Abbott Laboratories | $48.76 | 2025 | Cardiomems |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $46.75 | 2023 | Sotalol Hydrochloride |
| Penumbra, INC. | $44.28 | 2024-2025 | Indigo System |
| Esperion Therapeutics, INC. | $40.11 | 2025 | Nexletol |
| Cardiovascular Systems INC. | $39.57 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $31.44 | 2019-2020 | |
| Amarin Pharma, INC. | $25.81 | 2020-2021 | |
| Biosense Webster, INC. | $18.38 | 2022 | |
| Chiesi USA, INC. | $14.11 | 2025 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.